Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

2.60USD
23 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.60
Open
$2.60
Day's High
$2.65
Day's Low
$2.58
Volume
5,760
Avg. Vol
215,975
52-wk High
$4.08
52-wk Low
$2.25

Select another date:

Mon, May 8 2017

BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million

* AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

BRIEF-Acelrx Pharmaceuticals Q4 loss per share $0.21

* Acelrx Pharmaceuticals reports fourth quarter and year end 2016 financial results

BRIEF-Acelrx says U.S. app to market painkiller Dsuvia accepted by FDA

* Acelrx pharmaceuticals' new drug application for dsuvia accepted for filing with pdufa date of october 12, 2017

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Select another date:

More From Around the Web